Contains Nonbinding Recommendations
IX.
REFERENCES
1. Guidance for Industry: Process Validation: General Principles and Practices, January 2011,
https://www.fda.gov/media/71021/download.
2. Guidance for Industry: Content and Format of Chemistry, Manufacturing and Controls
Information and Establishment Description Information for a Vaccine or Related Product,
January 1999, https://www.fda.gov/media/73614/download.
3. Perlman S and Dandekar AA, 2005, Immunopathogenesis of Coronavirus Infections:
Implications for SARS, Nat Rev Immunol 5: 917-927, https://doi.org/10.1038/nri1732.
4. Haagmans BL, Boudet F, Kuiken T, deLang A, et al., 2005, Protective immunity induced by
the inactivated SARS coronavirus vaccine, Abstract S 12-1 Presented at the X International
Nidovirus Symposium, Colorado, Springs, CO.
5. Tseng C-T, Sbrana E, Iwata-Yoshikawa N, Newman P, et al., 2012, Immunization with SARS
Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS
Virus, PloS One, 7(4): e35421,
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035421.
6. Yasui F, Kai C, Kitabatake M, Inoue S, et al., 2008, Prior Immunization With Severe Acute
Respiratory Syndrome (SARS) – associated Coronavirus (SARS-CoV) Nucleocapsid Protein
Causes Severe Pneumonia in Mice Infected with SARS-CoV, J Immunol, 181(9): 6337-6348,
https://www.jimmunol.org/content/181/9/6337.long.
7. Bolles M, Deming D, Long K, Agnihothram S, et al., 2011, A Double-Inactivated Severe
Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection In Mice
And Induces Increased Eosinophilic Proinflammatory Pulmonary Response Upon Challenge,
J Virol 85(23) 12201-12215, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3209347/.
8. Agrawal AS, Tao X, Algaissi A, Garron T, et al., 2016, Immunization With Inactivated
Middle East Respiratory Syndrome Coronavirus Vaccine Leads To Lung Immunopathology
On Challenge With Live Virus, Hum Vaccin Immunother, 12(9): 2351-2356,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027702/.
9. Guidance for Industry: Considerations For Plasmid DNA Vaccines For Infectious Disease
Indications, November 2007, https://www.fda.gov/media/73667/download.
10. Guidance for Industry: Considerations For Developmental Toxicity Studies For Preventive
And Therapeutic Vaccines For Infectious Disease Indications, February 2006,
https://www.fda.gov/media/73986/download.